Arginase

L-Ornithine ((S)-2,5-Diaminopentanoic acid) exhibits an anti-fatigue function by promoting ammonia excretion and enhancing energy consumption efficiency.

Nω-Hydroxy-nor-L-Arginine Dihydrochloride is a competitive and reversible inhibitor of arginase

nor-NOHA monoacetate (Nω-Hydroxy-nor-L-arginine) is a highly potent and selective arginase inhibitor. nor-NOHA monoacetate inhibits rat hepatic arginase and inhibits the hydrolysis of L-arginine, which can be used to study cardiovascular and obstructive airway diseases.

Guanidine hydrochloride (Aminoformamidine Hydrochloride) is a strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant.

BEC hydrochloride (BEC HCl) is a competitive arginase inhibitor, which bind slowly. Ki of BEC HCl is 0.31 μM (pH7.5) for Arginase II, and is 0.4-0.6 μM for rat Arginase I.

Piceatannol 3'-O-glucoside (Piceatannol 3-glycoside) increases pulmonary blood oxygen tension and decreases pulmonary interstitial edema, so it can protect lung injury.

L-Norvaline is an arginase inhibitor and a non-protein branched-chain amino acid. L-Norvaline has previously been reported as a natural component of the antifungal peptide of Bacillus subtilis. L-Norvaline and other modified branched-chain amino acids have received attention in recent studies because they appear to be incorporated into some recombinant proteins found in E. coli.

Urea (Carbonyldiamide) is formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end metabolite of protein catabolism and accounts for about one-half of the total urinary solids.

DL-Norvaline (2-Aminopentanoic acid) is a non-competitive inhibitor of arginase.

nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a reversible inhibitor of arginase with anti-leukemic activity, effective in treating endothelial dysfunction, immunosuppression, and metabolism regulation.

OATD-02 is an orally active, competitive, reversible, noncovalent inhibitor with slow offset kinetics that targets both Arginase1 and Arginase2, exhibiting inhibitory concentrations (IC50) of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1). Notably, OATD-02 mitigates tumor immunosuppression provoked by these arginases and has potential application in melanoma research [1].

ARG1-IN-1 hydrochloride is a potent inhibitor of human arginase 1, exhibiting an IC50 value of 29 nM [1].